• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Integrated Solutions for Continuous Manufacturing in Oral Solid Dosage Forms

contractpharmaApril 03, 2019

Tag: Development , dosage

April 3, 11:30 a.m. - 12:15 p.m., MG America - Booth 2221

Speakers:
Marco Bellentani, Product Manager & Validation Manager, MG2 S.r.l.
Richard Steiner, Business Development Manager, GEA Pharma System

Register as Visitor to CPhI China 2019!

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Pall, ARTeSYN Biosolutions Expand Single-Use Technology Alliance

Next:Dr. Gustavo Mahler Resigns as Chief Executive Officer of AGC Biologics, Patricio Massera to Succeed as CEO Effective May 1st, 2019

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Integrated Solutions for Continuous Manufacturing in Oral Solid Dosage Forms | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

OTHER DOSAGE FORMS

OTHER DOSAGE FORMS
Medicinal (Injection,Oral or External Dosage Forms)Bottles

Medicinal (Injection,Oral or External Dosage Forms)Bottles
Drug Development & CMC

Drug Development & CMC
Ropivacaine underdevelopment

Ropivacaine underdevelopment
Ear spray pump with different dosage

Ear spray pump with different dosage
Solid Dosage production line

Solid Dosage production line
Metaraminol bitartrate underdevelopment

Metaraminol bitartrate underdevelopment
Formulation development

Formulation development
Tolvaptan underdevelopment

Tolvaptan underdevelopment
Big Dosage Transfusion Liquid Filling Production Line

Big Dosage Transfusion Liquid Filling Production Line

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service